Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial

• DOI: 10.5812/hepatmon.114781
• Publication Date: 2021-10-26T11:47:28Z
• Authors: Andrew Seaman; Wren Ronan; Lauren Myers; Haven Wheelock; Melinda Butler; Lisa Nelson; Beth E. Williams; Atif Zaman
• Keywords: Discontinuation; Hepatitis C

Background: Hepatitis C Virus (HCV) treatment in people who inject drugs (PWID) is a key component of elimination models but PWID face substantial barriers to access. Despite data showing outcomes among on medications for opioid use disorder (MOUD) are similar non-PWID outcomes, few studies examine with only syringe services support. Objectives: To evaluate the effect recruitment HCV elbasvir/grazoprevir (E/G) program (SSP) as compared an MOUD disorder. Methods: This real-world, multi-site prospective open-label pilot study compares aspartate aminotransferase platelet ratio (APRI) < 0.7 and genotype 1a, 1b, 4 E/G, engaged (n = 25) or SSP 25). The arm was enrolled through federally qualified community health center nearby SSP. Prospective arms were academic hepatology clinic group 50). Sustained virologic response at 12 weeks (SVR12), medication adherence, discontinuation evaluated. Results: In vs arms, substance throughout found 36% (9/25) 100% (25/25); good adherence (> 90% pills taken) (25/25) 68% (17/25); completion 64% (16/25); SVR12 rates 96% (24/25) 60% (15/25). standard comparison group, achieved 94% (47/50). There two failures re-infections group; all other non-responders due missing data. Conclusions: While follow-up challenging SSPs, preliminary suggests completion, high treated E/G engaging MOUD. All metrics comparable standards direct-antiviral drugs.